Clinical translation requires human CSF pharmacokinetic assays to prove BBB bypass, a rigorous dose-escalation Phase I trial to establish a safe human NOAEL for chronic dosing, and an RCT utilizing precise neurocognitive testing (e.g., MoCA) to confirm that murine transcriptomic shifts yield functional neuroprotection in humans
GLP-1 Effectiveness, Mechanisms of Action and Potential Part 1 An Image/Link below is provided (as is) to download presentation Download Policy: Content on the Website is provided to you AS IS for your information and personal use and may not be sold / licensed / shared on other websites without getting consent from its author
These medicines include injectable formulations such as semaglutide (Ozempic, Wegovy), dulaglutide (Trulicity), liraglutide (Victoza, Saxenda), and exenatide (Byetta, Bydureon BCise), as well as oral semaglutide (Rybelsus)
Potent GLP-1 agonists exert effects by multiple mechanisms including delayed gastric emptying, increased glucose-dependent insulin secretion, reduced glucagon levels, and reduced food intake by CNS effects to cause appetite suppression
Navigating this path requires a plan that prioritizes your safety and your long-term physical health
Drugs currently being tested that target AATs are shown in (Table 1)